Safety and Activity of Programmed Cell Death-1 Knockout Engineered T Cells in Patients With Previously Treated Advanced Esophageal Squamous Cell Carcinoma: An Open-label, Single-arm Phase 1 Study
NCT03081715 · COMPLETED · N/A
We track 1 ClinicalTrials.gov studies led by Hangzhou Cancer Hospital. The portfolio skews toward N/A (1 trials).
1 clinical trials sponsored by Hangzhou Cancer Hospital.
| Phase | Trials | Distribution |
|---|---|---|
| N/A | 1 | 100% |
Hangzhou Cancer Hospital currently sponsors 1 clinical trials tracked on ReadTheTrial. These span N/A.
Hangzhou Cancer Hospital conducts research across multiple therapeutic areas. Browse the trial listings for details.
Check the trial listings below for current recruitment status. Trial recruitment status can change frequently.